Skip to main content
Caplight Logo









AshiBio

AshiBio

Private
Burlingame, CaliforniaHealthcare & Life Scienceshttps://ashibio.com/

Last Round

Series A

Jun 20, 2024

Total Funding Raised

$40M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

AshiBio is a biotechnology company that develops innovative therapies aimed at preventing symptoms and slowing disease progression for patients with rare bone and connective tissue disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyrare disease therapeuticsmonoclonal antibodydrug developmentclinical-stage biotechorphan drugfibrodysplasia ossificans progressivaFOPautosomal dominant osteopetrosisADO2MMP-9 inhibitorclinical trialsbone disorder treatmentbiopharmadrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AshiBio Comparables

Compare AshiBio with similar companies based on industry and business-model similarity.

AshiBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ipsen
75%
Mereo BioPharma Group plc
72%
SiSaf Ltd
71%

AshiBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 20, 2024

Key People

Founding team and executive leadership

Joe Sarret

Acting Chief Operating Officer

Executive Team

AshiBio Investors

Notable investors and investment history

AshiBio investors
InvestorRounds
Agent CapitalSeries A
MPM BioImpactSeries A, Seed
Mirae Asset Venture InvestmentSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 20, 2026

    Monthly visitors increased 32% MoM, reaching 2K.

  • Jun 20, 2024

    $40M round with participation from Mirae Asset and Agent Capital.

AshiBio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

AshiBio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AshiBio's valuation, stock price, and market status.

Firmographic Details

HeadquartersBurlingame, California
Employee Range7
Year Founded2022
Last FundingJun 20, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?